Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-netrin-1 monoclonal antibody NP137

A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the laminin-related protein netrin-1 (NTN1), with potential antineoplastic activity. Upon administration, anti-NTN1 monoclonal antibody NP137 targets, binds to and neutralizes NTN1, thereby preventing its binding to and activation of NTN1 receptors. By blocking NTN1, NP137 is able to restore apoptosis in tumor cells. This inhibits tumor growth and metastasis. NTN1, overexpressed by a variety of cancers, plays a key role in promoting tumor initiation, progression, proliferation, adhesion, invasion, survival and modulation of tumor+F52:J54 plasticity and the tumor microenvironment (TME).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-NTN1 MoAB NP137
Code name:NP 137
NP-137
NP137
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search